On April 22, 2026, NCCN will host a specialized clinical program titled “Optimizing Patient Outcomes – In a Blink of an Eye: Updates in Frontline Therapy with Blinatumomab for Pediatric Acute Lymphoblastic Leukemia.”

While pediatric ALL survival rates have improved significantly over decades, the integration of blinatumomab into upfront therapy for newly diagnosed B-cell ALL represents a landmark shift in the treatment landscape. This session will provide healthcare professionals with a deep dive into risk-stratified approaches, evidence-based data on frontline blinatumomab use, and the potential for targeted therapies to de-intensify conventional chemotherapy, ultimately shaping the future of pediatric oncology.

Register now.